H.K., Hazekamp, A. et al. (2004). Metabolomic differentiation of Cannabis sativa cultivars using 1H NMR spectroscopy and principal component analysis. J. Nat. Prod. 67: 953–957.8 ElSohly, M.A. and Slade, D. (2005). Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 78: 539–548.
9 ElSohly, M.A., El-Feraly, F.S., and Turner, C.E. (1977). Isolation and characterization of (+)-cannabitriol and (−)-10-ethoxy-9-hydroxy-D6a(10a)-tetrahydrocannabinol: two new cannabinoids from Cannabis sativa L. extract. Lloydia 40 (3): 275–280.
10 ElSohly, H.N., Boeren, E.G., Turner, C.E., and ElSohly, M.A. (1984). Constituents of Cannabis sativa L. XXIIII: cannabitetrol, a new polyhydroxylated cannabinoid. In: The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects (eds. S. Agurell, W.L. Dewey and R.E. Willette), 89–96. New York: Academic Press.
11 Elzinga, S., Fischedick, J., Podkolinski, R., and Raber, J.C. (2015). Cannabinoids and terpenes as chemotaxonomic markers in Cannabis. Nat. Prod. Chem. Res. 3: 181.
12 Fellermeier, M., Eisenreich, W., Bacher, A., and Zenk, M.H. (2001). Biosynthesis of cannabinoids: incorporation experiments with 13C-labeled glucoses. Eur. J. Biochem. 268: 1596–1604.
13 Fischedick, J., Van Der Kooy, F., and Verpoorte, R. (2010a). Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chem. Pharm. Bull. 58: 201–207.
14 Fischedick, J.T., Hazekamp, A., Erkelens, T. et al. (2010b). Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry 71: 2058–2073.
15 Flores-Sanchez, I.J. and Verpoorte, R. (2008). Secondary metabolism in Cannabis. Phytochem. Rev. 7: 615–639.
16 Flores-Sanchez, I.J., Pčc, J., Fei, J. et al. (2009). Elicitation studies in cell suspension cultures of Cannabis sativa L. J. Biotechnol. 143: 157–168.
17 Formukong, E.A., Evans, A.T., and Evans, F.J. (1988). Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12: 361–371.
18 Galal, A.M., Slade, D., Gul, W. et al. (2009). Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Pat. CNS Drug Discov. 4: 112–136.
19 Giacoppo, S., Mandolino, G., Galuppo, M. et al. (2014). Cannabinoids: new promising agents in the treatment of neurological diseases. Molecules 19: 18781–18816.
20 Grote, H. and Spiteller, G. (1978a). New cannabinoids II. J. Chromatogr. 154: 13–23.
21 Grote, H. and Spiteller, G. (1978b). New cannabinoids. The structure of cannabicoumaronone and analogous compounds. Tetrahedron 34: 3207–3213.
22 Gubellini, P., Picconi, B., Bari, M. et al. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22: 6900–6907.
23 Hampson, A.J., Grimaldi, M., Axelrod, J., and Wink, D. (1998). Cannabidiol and (−)D9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. U.S.A. 95: 8268–8273.
24 Hanuš, L.O., Meyer, S.M., Muňoz, E. et al. (2016). Phytocannabinoids: a unified critical inventory. Nat. Prod. Rep. 33: 1357–1392.
25 Happyana, N., Agnolet, S., Muntendam, R. et al. (2013). Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry 87: 51–59.
26 Hartsel, S.C., Loh, W.H.T., and Robertson, L.W. (1983). Biotransformation of cannabidiol to cannabielsoin by suspension cultures of Cannabis sativa and Saccharum officinarum. Planta Med. 48: 17–19.
27 Hillig, K.W. (2004). A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochem. Syst. Ecol. 32: 875–891.
28 Jiang, H.-E., Li, X., Zhao, Y.-X. et al. (2006). A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. J. Ethnopharmacol. 108: 414–422.
29 Johnson, K.A., Conn, P.J., and Niswender, C.M. (2009). Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 8: 475–491.
30 Kajima, M. and Piraux, M. (1982). The biogenesis of cannabinoids in Cannabis sativa. Phytochemistry 21: 67–69.
31 Lewis, M.M., Yang, Y., Wasilewski, E. et al. (2017). Chemical profiling of medical Cannabis extracts. ACS Omega 2: 6091–6103.
32 Li, H.-L. (1973). The origin and use of Cannabis in Eastern Asia: linguistic-cultural implications. Econ. Bot. 28: 293–301.
33 Mackie, K., Devane, W.A., and Hille, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44: 498–503.
34 Mahlberg, G. and Kim, E.S. (2004). Accumulation of cannabinoids in glandular trichomes of Cannabis (Cannabaceae). J. Ind. Hemp 9: 15–36.
35 Manduca, A., Campolongo, P., and Trezza, V. (2012). Cannabinoid modulation of mother-infant interaction: is it just about milk? Rev. Neurosci. 23: 707–722.
36 Morimoto, S., Komatsu, K., Taura, F., and Shoyama, Y. (1998). Purification and characterization of cannabichromenic acid synthase from Cannabis sativa. Phytochemistry 49: 1525–1529.
37 Morimoto, S., Tanaka, Y., Sasaki, K. et al. (2007). Identification and characterization of cannabinoids that induce cell death through mitochondrial permeability transition in Cannabis leaf cells. J. Biol. Chem. 282: 20739–20751.
38 Nascimento, I.R., Costa, H.B., Souza, L.M. et al. (2015). Chemical identification of cannabinoids in street marijuana samples using electrospray ionization FT-ICR mass spectrometry. Anal. Methods 7: 1415–1424.
39 Pacifico, D., Miselli, F., Carboni, A. et al. (2008). Time course of cannabinoid accumulation and chemotype development during the growth of Cannabis sativa L. Euphytica 160: 231–240.
40 Pate, D.W. (1983). Possible role of ultraviolet radiation in evolution of Cannabis chemotypes. Econ. Bot. 37: 396–405.
41 Pisani, A., Fezza, F., Galati, S. et al. (2005). High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57: 777–779.
42 Pisani, V., Moschella, V., Bari, M. et al. (2010). Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov. Disord. 25: 920–924.
43 Pisani, V., Madeo, G., Tassone, A. et al. (2011). Homeostatic changes of the endocannabinoid system in Parkinson's disease. Mov. Disord. 26: 216–222.
44 Radwan, M.M., Ross, S., Slade, D. et al. (2008). Isolation and characterization of new Cannabis constituents from a high potency variety. Planta Med. 74: 267–272.
45 Radwan, M.M., Elsohly, M.A., Slade, D. et al. (2009). Biologically active cannabinoids from high-potency Cannabis sativa. J. Nat. Prod. 72: 906–911.
46 Radwan, M.M., ElSohly, M.A., El-Alfy, A.T. et al. (2015). Isolation and pharmacological evaluation of minor cannabinoids from high-potency Cannabis sativa. J. Nat. Prod. 78: 1271–1276.
47 Raharjo, T.J., Eucharia, O., Chang, W.-T., and Verpoorte, R. (2006). Callus induction and phytochemical characterization of Cannabis sativa cell suspension cultures. Indones. J. Chem. 6:
